16 May 2024 : Clinical Research
Prevalence and Management of Chronic Pain, Including Neuropathic Pain, in Dialysis Patients with End-Stage Renal Disease
Klaudia Kitala-Tańska
1ABDEF*, Ewa Kania-Zimnicka2AB, Damian Tański 3CDEF, Norbert Kwella 4BDE, Tomasz Stompór 4ADEF, Małgorzata Stompór 5ADEF
DOI: 10.12659/MSM.943808
Med Sci Monit 2024; 30:e943808
Table 5 Selected analgesics and nervous system–interacting medications given to patients with and without potential neuropathic pain.
| Groups of medicines (according to ATC code) | Chronic pain without neuropathic component (n=32)* | Probable neuropathic pain (n=29)* | Statistical significance |
|---|---|---|---|
| N02A Opioids** | 1 (3.13%) | 6 (20.69%) | p=0.04 |
| N02BE01 Paracetamol | 3 (9.38%) | 4 (13.79%) | p=NS |
| M01A Nonsteroidal anti-inflammatory drugs | 10 (31.25%) | 9 (34.62%) | |
| N03A Antiepileptics*** | 2 (6.25%) | 3 (10.35%) | |
| N05B Anxiolytic drugs | 0 (0.00%) | 1 (3.45%) | |
| N06A Antidepressants | 2 (6.25%) | 0 (0.00%) | |
| N05C Hypnotic and sedatives drugs | 2 (6.25%) | 0 (0.00%) | |
| * Percentages do not add up to 100 percent because a participant may have received more than one medication from separate groups; ** among patients receiving opioids: 6 received tramadol, 1 received fentanyl; *** among patients receiving antiepileptics: 2 received pregabalin, 1 received gabapentin, 1 received carbamazepine, 1 received levetiracetam. | |||